Co-develop bispecific antibodies! AbbVie's $750 million advance to Genmab

The two companies announced that AbbVie will make a $750 million advance payment to Genmab as part of a partnership to jointly develop and commercialize three next-generation bispecific antibodiesThe protocol includes Genmab's epcoritamab, also known as DuoBody-CD3xCD20 double resistanceIn addition to Genmab's Duo HexaBody-CD37 and DuoBody-CD3x5T4, the two companies will combine the benefits: Genmab's DuoBody technology and AbbVie's antibody-drug coupling technology to develop up to four next-generation candidate products, including solid and blood system malignanciesIn addition to the advances, Genmab will receive additional development, regulatory and sales milestone payments of up to $3.15 billion, as well as tiered royalties of 22 to 26 percent of epcoritamab's net sales outside the U.Sand JapanOf these, three existing bispecific antibody clinical development and commercialization milestones are paid up to $1.15 billion